Insulet stock
PODDNASDAQInsulet Corp., HealthcareISIN US45784P1012
65Score 65 out of 100, Neutral
Price and trend
51 / 100
Price history
−54% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since January 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 57% below its 52-week high. Largest decline in 19 years: 90% (November 2007 to March 2009).
Chart figures for advanced users
- SMA 50$142.08
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$173.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$130.47
- The lowest closing price of the last twelve months.
- Resistance$346.36
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Insulet Corp. belongs to the Medical (Devices) industry (United States) and, with a market value of $10.41B, is number 20 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.71B (up 30.7% year on year) and earnings of $247.1M (down 40.9%).
- For fiscal 2026, analysts expect on average revenue of $3.29B (up 21.5%) and adjusted earnings per share of $6.51 (up 30.7%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 216 of 714 in Healthcare, median 53.
- The P/E is 24.3 (Medical (Devices) median 29, own median of recent years 73.3).
- Our model puts fair value at $217.90, with the price 31% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 99.9% a year since 2020.Growth 88
- Growing faster than its industryRevenue up 24.5% a year since 2020, Medical (Devices) median 13.8%.Growth 88
- Below fair valuePrice 31% below the fair value of $217.90.Valuation 70
Weaknesses
- Share price fell sharplyDown 53% over the last 12 months.Momentum 44
- Volatile share priceVolatility 46% a year over the last 12 months.Stability 68
Its standout strengths are growth and profitability, while momentum holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high growth grade (crashed more often in the backtest)
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $155.64 and expensive above $363.17 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $256.65 (cash-flow model) and $179.15 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $194.90, at 7.8% it would be $252.54.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 26.5% on the twelve months before. Revenue has grown strongly since 2006, at around 42% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating 17%, net 9%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 17 Feb 2027in 97 days
- Last reported
- 4 Nov 2026EPS reported $1.99 (expected $1.59)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $6.51+0.1%
- Revenue
- $3.29B0.0%
- Earnings per share
- $7.72+0.3%
- Revenue
- $3.75B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −16.5%2026 revenue guidance lowered to 20% to 22% growth, mainly on weaker retention among type 2 customers, U.S. 17% to 19%, with only international raised to 30% to 32%.
“We now expect 2026 total company revenue growth of 20% to 22% and U.S. Omnipod growth of 17% to 19%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $562,610 in total. One insider sold, $59,887 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Insulet
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- PenumbraPEN $12.68B59
- Align TechnologyALGN $12.13B71
- Olympus7733.T $11.7B70
- DemantDEMANT.CO $11.62B73
- Bio-Rad LaboratoriesBIO $10.38B61
- Globus MedicalGMED $10.12B72
- BrukerBRKR $9.53B53
- GetingeGETI-B.ST $7.6B63
ETFs that hold Insulet
Held by 30 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 2.65% | 0.68% | €5.31M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.06% | 0.40% | €1.49B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.52% | 0.25% | €44.3M |
Show 5 more
| Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW | 0.21% | 0.15% | €14.88B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.16% | 0.15% | €3.27B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.16% | 0.15% | €592.11M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.13% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.11% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 19 Sep 2025)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.